Literature DB >> 2142531

Chromosome 17p deletions and p53 gene mutations associated with the formation of malignant neurofibrosarcomas in von Recklinghausen neurofibromatosis.

A G Menon1, K M Anderson, V M Riccardi, R Y Chung, J M Whaley, D W Yandell, G E Farmer, R N Freiman, J K Lee, F P Li.   

Abstract

von Recklinghausen neurofibromatosis (NF1) is a common hereditary disorder characterized by neural crest-derived tumors, particularly benign neurofibromas whose malignant transformation to neurofibrosarcomas can be fatal. The NF1 gene has been mapped to a small region of chromosome 17q, but neither the nature of the primary defect nor the mechanisms involved in tumor progression are understood. We have tested whether NF1 might be caused by the inactivation of a tumor suppressor gene on 17q, analogous to that on chromosome 22 in NF2, by searching for deletions of chromosome 17 in NF1-derived tumor specimens. Both neurofibrosarcomas from patients with "atypical" NF and 5 of 6 neurofibrosarcomas from NF1 patients displayed loss of alleles for polymorphic DNA markers on chromosome 17. However, the common region of deletion was on 17p and did not include the NF1 region of 17q. Since no loss of markers on chromosome 17 was observed in any of 30 benign tumors from NF1 patients, the 17p deletions seen in neurofibrosarcomas are probably associated with tumor progression and/or malignancy. This region contains a candidate gene for tumor progression, p53, which has recently been implicated in the progression of a broad array of human cancers. In a preliminary search for p53 aberrations by direct sequencing of polymerase chain reaction-amplified DNA from 7 neurofibrosarcomas, 2 tumors that contained point mutations in exon 4 of the p53 gene were found, suggesting a role for this gene in at least some neurofibrosarcomas. Thus the formation of malignant neurofibrosarcomas may result from several independent genetic events including mutation of the NF1 gene, whose mechanism of tumorigenesis remains uncertain, and subsequent loss of a "tumor suppressor" gene on 17p, most likely p53.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2142531      PMCID: PMC54339          DOI: 10.1073/pnas.87.14.5435

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  The p53 proto-oncogene can act as a suppressor of transformation.

Authors:  C A Finlay; P W Hinds; A J Levine
Journal:  Cell       Date:  1989-06-30       Impact factor: 41.582

Review 2.  Von Recklinghausen neurofibromatosis.

Authors:  V M Riccardi
Journal:  N Engl J Med       Date:  1981-12-31       Impact factor: 91.245

3.  Implantation of human meningiomas into the subrenal capsule of the nude mouse. A model for studies of tumor growth.

Authors:  A Medhkour; M Van Roey; R A Sobel; H J Fingert; J Lee; R L Martuza
Journal:  J Neurosurg       Date:  1989-10       Impact factor: 5.115

4.  Mutations in the p53 gene occur in diverse human tumour types.

Authors:  J M Nigro; S J Baker; A C Preisinger; J M Jessup; R Hostetter; K Cleary; S H Bigner; N Davidson; S Baylin; P Devilee
Journal:  Nature       Date:  1989-12-07       Impact factor: 49.962

5.  Oncogenic point mutations in the human retinoblastoma gene: their application to genetic counseling.

Authors:  D W Yandell; T A Campbell; S H Dayton; R Petersen; D Walton; J B Little; A McConkie-Rosell; E G Buckley; T P Dryja
Journal:  N Engl J Med       Date:  1989-12-21       Impact factor: 91.245

6.  Physical mapping of a translocation breakpoint in neurofibromatosis.

Authors:  J W Fountain; M R Wallace; M A Bruce; B R Seizinger; A G Menon; J F Gusella; V V Michels; M A Schmidt; G W Dewald; F S Collins
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

7.  Two NF1 translocations map within a 600-kilobase segment of 17q11.2.

Authors:  P O'Connell; R Leach; R M Cawthon; M Culver; J Stevens; D Viskochil; R E Fournier; D C Rich; D H Ledbetter; R White
Journal:  Science       Date:  1989-06-02       Impact factor: 47.728

8.  p53: a frequent target for genetic abnormalities in lung cancer.

Authors:  T Takahashi; M M Nau; I Chiba; M J Birrer; R K Rosenberg; M Vinocour; M Levitt; H Pass; A F Gazdar; J D Minna
Journal:  Science       Date:  1989-10-27       Impact factor: 47.728

9.  Molecular dissection of a contiguous gene syndrome: frequent submicroscopic deletions, evolutionarily conserved sequences, and a hypomethylated "island" in the Miller-Dieker chromosome region.

Authors:  D H Ledbetter; S A Ledbetter; P vanTuinen; K M Summers; T J Robinson; Y Nakamura; R Wolff; R White; D F Barker; M R Wallace
Journal:  Proc Natl Acad Sci U S A       Date:  1989-07       Impact factor: 11.205

10.  Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas.

Authors:  S J Baker; E R Fearon; J M Nigro; S R Hamilton; A C Preisinger; J M Jessup; P vanTuinen; D H Ledbetter; D F Barker; Y Nakamura; R White; B Vogelstein
Journal:  Science       Date:  1989-04-14       Impact factor: 47.728

View more
  89 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Pathology of peripheral nerve sheath tumors: diagnostic overview and update on selected diagnostic problems.

Authors:  Fausto J Rodriguez; Andrew L Folpe; Caterina Giannini; Arie Perry
Journal:  Acta Neuropathol       Date:  2012-02-12       Impact factor: 17.088

3.  Confirmation of a double-hit model for the NF1 gene in benign neurofibromas.

Authors:  E Serra; S Puig; D Otero; A Gaona; H Kruyer; E Ars; X Estivill; C Lázaro
Journal:  Am J Hum Genet       Date:  1997-09       Impact factor: 11.025

4.  Deletions of the INK4A gene occur in malignant peripheral nerve sheath tumors but not in neurofibromas.

Authors:  H P Kourea; I Orlow; B W Scheithauer; C Cordon-Cardo; J M Woodruff
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

5.  Mouse tumor model for neurofibromatosis type 1.

Authors:  K S Vogel; L J Klesse; S Velasco-Miguel; K Meyers; E J Rushing; L F Parada
Journal:  Science       Date:  1999-12-10       Impact factor: 47.728

6.  Malignant transformation of neurofibromas in neurofibromatosis 1 is associated with CDKN2A/p16 inactivation.

Authors:  G P Nielsen; A O Stemmer-Rachamimov; Y Ino; M B Moller; A E Rosenberg; D N Louis
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

7.  Expression of p27(kip) and other cell cycle regulators in malignant peripheral nerve sheath tumors and neurofibromas: the emerging role of p27(kip) in malignant transformation of neurofibromas.

Authors:  H P Kourea; C Cordon-Cardo; M Dudas; D Leung; J M Woodruff
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 8.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor.

Authors:  Nancy Ratner; Shyra J Miller
Journal:  Nat Rev Cancer       Date:  2015-04-16       Impact factor: 60.716

9.  Preclinical therapeutic efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral nerve sheath tumors.

Authors:  Vincent Chau; S Kyun Lim; Wei Mo; Chiachi Liu; Amish J Patel; Renée M McKay; Shuguang Wei; Bruce A Posner; Jef K De Brabander; Noelle S Williams; Luis F Parada; Lu Q Le
Journal:  Cancer Res       Date:  2013-11-27       Impact factor: 12.701

10.  Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Authors:  Syed J Kazmi; Stephanie J Byer; Jenell M Eckert; Amy N Turk; Richard P H Huijbregts; Nicole M Brossier; William E Grizzle; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Am J Pathol       Date:  2013-01-13       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.